As it di­gests Shire, Take­da plans to shed $10B in non-core as­sets to re­lieve debt bur­den

Af­ter con­sum­mat­ing his hefty $62 bil­lion deal to buy Shire, Take­da’s Christophe We­ber is deal­ing with the sticky is­sue of its bal­looned debt bur­den with di­vest­ments of around $10 bil­lion, the CEO of the biggest Japan­ese drug­mak­er told re­porters at the JP Mor­gan con­fer­ence on Tues­day.

The com­bined com­pa­ny, which is sad­dled with a re­port­ed $48 bil­lion in net debt af­ter the Shire takeover, is plan­ning to shed “non-core” as­sets, in­clud­ing busi­ness­es from the $13.7 bil­lion Ny­comed ac­qui­si­tion ex­e­cut­ed in 2011, ac­cord­ing to the Fi­nan­cial Times. Take­da $TAK bought the Swiss drug­mak­er for its smok­er’s lung drug and its OTC port­fo­lio in an at­tempt to ex­pand its foot­print in emerg­ing mar­kets, but as mar­ket con­di­tions wors­ened, the deal in­vit­ed a storm of crit­i­cism.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.